18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, Neurology, Neurology, Neurology, Psychiatric |
| Therapuetic Areas: | Immunology / Infectious Diseases, Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/10/2017 |
| Start Date: | June 2014 |
| End Date: | October 2015 |
18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy
This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic
encephalopathy (CTE) and examine the relationship between clinical presentation and tau
deposition.
encephalopathy (CTE) and examine the relationship between clinical presentation and tau
deposition.
Inclusion Criteria:
- Male subjects consented and currently enrolled in the Diagnosing and Evaluating
Traumatic Encephalopathy Using Clinical Tests (DETECT) or the Long-Term Consequences
of Repetitive Brain Injury in Athletes study protocols
- Can tolerate up to two PET imaging sessions
- Have the ability to provide informed consent for study procedures
Exclusion Criteria:
- Claustrophobia
- Current clinically significant cardiovascular disease or clinically significant
abnormalities on screening ECG
- History of risk factors for Torsades de Pointes or are taking drugs known to cause
QT-prolongation
- Current clinically significant infectious disease, endocrine or metabolic disease,
pulmonary, renal or hepatic impairment, or cancer that the investigator believes
would affect study participation or scan results
- Have had a non-study related radiopharmaceutical imaging or treatment within 7 days
prior to study PET imaging sessions
We found this trial at
2
sites
Click here to add this to my saved trials
Boston University Boston University is no small operation . With over 33,000 undergraduate and graduate...
Click here to add this to my saved trials